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Abstract Human malignant melanoma cell line
UACC903 is resistant to apoptosis while chromosome
6-mediated suppressed cell line UACC903(+6) is sensi-
tive. Here, we describe identiﬁcation of differential
molecular pathways underlying this difference. Using our
recently developed mitochondria-focused cDNA micro-
arrays, we identiﬁed 154 differentially expressed genes
including proapoptotic (BAK1 [6p21.3], BCAP31, BNIP1,
CASP3, CASP6, FAS, FDX1, FDXR, TNFSF10 and
VDAC1) and antiapoptotic (BCL2L1, CLN3 and MCL1)
genes. Expression of these pro- and anti-apoptotic genes
was higher in UACC903(+6) than in UACC903 before UV
treatment and was altered after UV treatment. qRT-PCR
and Western blots validated microarray results. Our bio-
informatic analysis mapped these genes to differential
molecular pathways that predict resistance and sensitivity
of UACC903 and UACC903(+6) to apoptosis respectively.
The pathways were functionally conﬁrmed by the FAS
ligand-induced cell death and by siRNA knockdown of
BAK1 protein. These results demonstrated the differential
molecular pathways underlying survival and apoptosis of
UACC903 and UACC903(+6) cell lines.
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Introduction
Human cutaneous malignant melanoma (CMM) reigns as
the most deadly form of skin cancer, responsible for 75%
of all skin cancer-related deaths [1]. The incidence of
melanoma continues to increase in western populations—
the number of cases worldwide has doubled in the past
20 years [2]. CMM frequently results from transformation
of melanocytes in the skin. High resistance to treatment is a
unique hallmark of malignant melanoma, although the
mechanisms by which melanoma cells protect themselves
against induced apoptosis remains largely unknown [3].
Many tumor cells bypass the apoptotic machinery through
mechanisms that may involve dysregulation of pro- and
anti-apoptotic genes [4]. Cytogenetic and molecular studies
have mapped frequent chromosomal breaks and deletions
on chromosomes 1, 6, 7, 9, 10, 11, and 19, and associated
these abnormalities with the development and progression
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DOI 10.1007/s10495-008-0231-8of CMM [5–7]. In particular, chromosome 6 abnormalities
have been found in[80% cases [8–11] and are believed to
play a key role in progression of CMM. Supporting this
notion, introduction of a neo-tagged normal chromosome 6
into human malignant melanoma cell lines results in sup-
pression of tumorigenicity [12] and metastasis [13, 14], and
enhancement of apoptosis [15]. These structural and
functional studies strongly suggest that multiple genes on
chromosome 6 play a causal role in the development and
progression of CMM.
The genetically linked human melanoma cell lines
UACC903 and UACC903(+6) phenotypically exhibit dis-
tinctive characteristics. Speciﬁcally, the parental UACC903
cell line demonstrates rapid population-doubling time,
focus formation in monolayer culture, anchorage-indepen-
dent growth, and rapid formation of s.c. tumors in athymic
nude mice. In contrast, the UACC903(+6) cell subline
shows suppression of all these phenotypes [12]. Using these
two cell lines, we previously identiﬁed the chromosome
6-encoded tumor suppressor gene connexin 43 which par-
tially explains the suppression of tumorigenic phenotypes as
a consequence of the introduced chromosome 6 [16, 17].
Recently, we demonstrated signiﬁcant differences between
UACC903 and UACC903(+6) cell lines in apoptosis and
cell distribution in G0/G1-, S- and G2/M-phases of the cell
cycle before and after UV irradiation [15]. The apparent
apoptotic difference strongly suggests the presence of dif-
ferential molecules that regulate survival and apoptosis.
In this report, we describe the identiﬁcation of differ-
entially expressed genes in the survival-apoptosis signaling
pathways that account for differences in apoptosis between
UACC903(+6) and UACC903 cell lines before and after
UV irradiation. Using human mitochondria-focused cDNA
microarrays [18], we identify gene expression proﬁles
before (0-h) and at 1.5-, 3-, 6- and 12-h after UV treatment.
After qRT-PCR validation of microarray results, we iden-
tiﬁed 154 differentially expressed genes of which 104
changes their expression in response to UV treatment,
suggesting differential regulation in these two cell lines.
Bioinformatics analysis revealed 16 genes relevant to
proapoptosis, 3 to antiapoptosis, 5 to DNA damage repair
and 1 to the G2 check point. We mapped these proapop-
totic and antiapoptotic genes to known survival-apoptosis
signaling pathways. Western blots conﬁrmed expression
changes of proapoptotic proteins BAK1 (encoded by
chromosome 6p21.3) and FAS, and antiapoptotic proteins
BCL2L1 and MCL1. Our MTS assay revealed that the FAS
ligand (FASLG)-induced cell death was both dose- and
time- responsive in these two cell lines. Moreover, siRNA
knockdown of the BAK1 protein in UACC903(+6) cells
resulted in increased survival and attenuation of FASLG-
induced cell death. These results demonstrate chromosome
6-encoded BAK1-involved differential survival-apoptosis
signaling pathways as the molecular mechanism underly-
ing resistance and sensitivity to apoptosis of human CMM
cell line UACC903 and the chromosome 6-mediated sup-
pressed cell subline UACC903(+6). These pathways have
implications for therapeutic research.
Methods and materials
Cell culture
UACC903 and UACC903(+6) cell lines were originally
obtained from University of Arizona Cancer Center [12].
UACC903 cells were cultured in RPMI1640 with 10% fetal
bovine serum, 2 mM L-glutamine. UACC903(+6) cells
were cultured in the same medium with 600 lg/ml G418 to
select for the pSV2neo-tagged chromosome 6.
UV irradiation
After removing medium, cells at 90% conﬂuence in 100-
mm dishes were exposed to UV (254 nm) generated by UV
Crosslinker (Model BLX254, Life Technologies, Gai-
thersburg, MD) at the dose of 40-J/M
2. Medium was added
immediately to continue culture until designated time
points. Cells at 0 h had no UV treatment.
Flow cytometry
It was performed by previously described methods [19, 20].
Both attached and ﬂoating cells were harvested for cell
cycle analysis. For each experiment, 10,000 cells were
analyzed using ELITE Flow Cytometry (Beckman Coulter,
Fullerton, CA) and Cell Quest software (Becton Dickinson,
Franklin Lakes, NJ).
TUNEL assay
Terminal DNA transferase-mediated dUTP biotin nick end
labeling (TUNEL) assay was employed to determine
in situ apoptotic DNA breaks [21, 22] by using the
Detection Kit (Roche Applied Sciences, Germany) fol-
lowing manufacturer’s instructions. Cells attached to glass
slides in culture dishes were subjected to TUNEL assay
and were then analyzed under Olympus BX 60 ﬂuorescent
microscope using Evolution CCD System and ImagePro
software (Media Cybernetics, Rockville, MD).
hMitChip3 microarray
A third-generation human mitochondria-focused cDNA
microarray (hMitChip3) containing 37 mitochondrial
DNA-encoded genes, 1,098 nuclear DNA-encoded and
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123mitochondria-related genes and 225 controls were printed
as described previously [18]. Total RNA was extracted
using Trizol reagent (Invitrogen) and puriﬁed with RNeasy
kit (Qiagen, Valencia, CA), as previous description [23].
Ten micrograms of RNA per sample were used for
microarray labeling and hybridization as previously
described [18]. Slides were scanned using the ScanArray
Express Microarray Scanner (PerkinElmer, Boston, MA) as
described previously [18].
Microarray data analysis
Microarray database construction, data ﬁltering and nor-
malizationwereperformedasdescribedpreviously[18].The
normalized data were used to cluster genes by using Eisen’s
Cluster software [24] and to calculate differentially expres-
sed genes. Heat map was visualized by using Maple Tree
(http://rana.lbl.gov/EisenSoftware.htm). Gene identiﬁers
includingcloneID,accessionnumber, UnigeneID,gene ID,
symbol and name were updated according to human Uni-
Gene Build 204 (ftp://ncbi.nih.gov/repository/UniGene/).
Gene ontology and pathways were downloaded from Entrez
(ftp://ncbi.nlm.nih.gov/gene). Ingenuity Pathway Analysis
software IPA 5.0 (Redwood City, CA) was used to map
pathways.
Quantitative RT-PCR (qRT-PCR)
Two micrograms of total RNA per sample were reverse-
transcribed into cDNA by using SuperScript
TM First-Strand
Synthesis System (Invitrogen). Thirty nanograms of each
cDNA sample was used for 40 cycles of qPCR analysis with
the Universal PCR Master Mix on an Applied Biosystems
7300 Real Time PCR System and Software (Applied Bio-
systems, Foster City, CA), following the manufacturer
instructions. Triplicate qPCR experiments were performed
foreach gene. RelativeRNAconcentrations were calculated
using the published methods [23, 25]. TaqMan probes and
primers for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, 4352934E); Fanconi anemia complementation
group D2 (FANCD2, Hs00276992_m1); DEAH (Asp-Glu-
Ala-His) box polypeptide 16 (DHX16, Hs00374356_m1);
adenosylmethionine decarboxylase 1 (AMD1, Hs007508
76_s1); BCL2-like 1 (BCL2L1, Hs99999146_m1); uracil-
DNA glycosylase (UNG, Hs00422172_m1); Fas TNF
receptor superfamily member 6 (FAS, Hs00531110_m1);
BCL2-antagonist/killer 1 (BAK1, Hs00832876_g1); cas-
pase 3 apoptosis-related cysteine peptidase (CASP3,
Hs00234387_m1); protein phosphatase 2 catalytic subunit
alpha isoform (PPP2CA, Hs00427259_m1); and myeloid
cell leukemia sequence 1 (MCL1, Hs03043898_m1) were
purchased from Applied Biosystems.
FAS ligand (FASLG)-induced apoptosis
Human recombinant soluble FASLG was purchased from
the Kamiya Biomedical Company (Seattle, WA). 4,000 and
5,000 cells in 20-ll media were plated into a 96 well plate
for cell lines UACC903 and UACC903(+6), respectively.
The dose-response curves were determined for FASLG at
the ﬁnal concentrations of 0, 50, 100, 200 and 400 ng/ml.
Cells were incubated for 22 h after addition of FASLG and
viable cells were measured by MTS cell proliferation
assay. The time–response curves were determined for
100 ng/ml of FASLG at the time points of 0, 1.5, 3, 6, 12,
and 24 h after UV treatment.
MTS cell proliferation assay
The CellTiter 96 AQueous One Solution Cell Proliferation
Assay kit (Promega, Madison, WI) was used to assess
number of viable cells following manufacturer’s instruc-
tions. Twenty microliters MTS reagent was added to cells
in 100-ll media in a well of 96-well plates. After incuba-
tion at 37C (5% CO2) for 2 h, viable cells were measured
at 490-nm absorbance with spectrophotometer SPEC-
TRAmax (Molecular Devices, Sunnyvale, California).
Background absorbance was recorded with control cells.
After subtraction of the background, absorbance was con-
verted to cell number based on standard curves generated
from UACC903 and UACC903(+6) cells for plotting
dose– and time–response curves.
siRNA experiments
BAK1 siRNA duplex, transfection reagents and mock
control (non-speciﬁc siRNA) were purchased from Ambion
(Austin, TX) and used following the manufacturer’s
instructions. Brieﬂy, transfection and knockdown efﬁcien-
cies of siRNA were optimized as 6 9 10
5 cells/ml for
UACC903(+6) by use of the manufacturer-provided
GAPDH siRNA and KDalert GAPDH Assay Kit. At 80–
90% conﬂuence, cells in monolayer culture were lifted with
0.05% Trypsin. Cell numbers were determined by use of a
Coulter Particle Counter (Model Z18, Beckman-Coulter
Inc., Miami, FL). Transfection reagents (siPORT NeoFX)
and stock siRNA were combined and incubated at room
temperature for 45-min. Twenty microliters of siPORT
NeoFX and siRNA (40 nM ﬁnal concentration) reaction
mixture was placed into each well of a 96 well plate, fol-
lowed by addition of 80-ll cell suspension. After
incubation for 48 h, 20-ll MTS reagent was added to
measure viable cells at 490-nm absorbance with spectro-
photometer SPECTRAmax (Molecular Devices). All
experiments were performed in triplicate.
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123Western blots analysis
Cells were harvested at indicated time points. Protein
concentration of cell lysate was determined by using DC
Protein Assay Kit (Bio-Rad, Hercules, CA). Approximately
30 lg of protein were subjected to electrophoresis in 12%
denatured SDS-polyacrylamide gel. Proteins in gel were
transferred to the Improved Polyscreen PVDF Transfer
Membrane (PerkinElmer Life Science Inc., Boston, MA) as
described by the manufacturer. Mouse monoclonal anti-
bodies (anti-FAS [B-10, Cat.# sc-8009] and anti-BCL2L1
[H-5, Cat.# sc-8392]) and rabbit polyclonal antibodies
(anti-BAK1 [H-211, Cat.# sc-7873] and anti-MCL1 [k-20,
Cat.# sc-958]) were from Santa Cruz Biotechnology (Santa
Cruz, CA); and mouse monoclonal antibody (anti-GAPDH
[6c5, Cat.# AM4300]) was from Ambion (Austin, TX).
BAK1, FAS, MCL1 and BCL2L1 antibodies were diluted
at 1:500 and GAPDH antibody was diluted at 1:20,000 to
detect the corresponding proteins. Secondary antibodies
used were horseradish peroxidase-conjugated anti-rabbit or
anti-mouse antibodies (Santa Cruz Biotechnology). Blots
were visualized by the ECL Western blotting detection
reagents (PerkinElmer LAS, Austin, TX) and X-ray ﬁlms.
Images were scanned and quantiﬁed by using Scanalytics
IPLAB 3.6 (Rockville, MD).
Statistics
Statistical calculations were performed on triplicate array
experiments using XLSTAT 2006 (XLSTAT, New York,
NY). Differentially expressed genes were identiﬁed by
equal to or greater than 1.5-fold change in the average
expression of the background-subtracted mean intensity
ratios of a gene between cell lines and/or between time
points. The level of statistical signiﬁcance was set at a
P-value\0.05.
Results
Apoptosis of UACC903(+6) and G2/M arrest of
UACC903 before and after UV treatment
To characterize apoptotic responses of human malignant
melanoma cell line UACC903 and chromosome 6-medi-
ated suppressed cell subline UACC903(+6), we compared
apoptosis rates and distribution rates of cells in the cell
cycle derived from TUNEL assay and ﬂow cytometry,
respectively. The results indicated that TUNEL-positive
apoptotic cells were 2.3 ± 0.6% in the UACC903 popu-
lation and 9.6 ± 1.1% in the UACC903(+6) before UV
irradiation (P\0.001), compared to 12.1 ± 2.1% and
51.0 ± 8.9%, respectively, 12 h after UV treatment
(P\0.0001) (Fig. 1). The levels of G2/M arrested cells
exhibited another major difference between the two cell
lines. The G2/M-phase cells were 16.9 ± 0.3% in the
UACC903 population and 13.2 ± 0.5% in UACC903(+6)
before UV treatment (P\0.001), compared to 27.0 ±
0.7% and 15.7 ± 0.1%, respectively, 24 h after UV treat-
ment (P\0.001). Thus, while apoptosis occurred in
UACC903(+6) cells, G2/M arrest was a major event in
UACC903 cells.
Expression clusters of 154 genes in UAC903(+6)
and UACC903 cells before and after UV treatment
To investigate the molecular mechanism underlying the
differential apoptosis between UACC903 and UACC903
(+6), we identiﬁed expression proﬁles of 154 signiﬁcantly
(P\0.05) differentially expressed genes between these
two cell lines before and at 1.5, 3, 6 and 12 h after UV
treatment using the hMitChip3 microarray (Supplemental
Table 1). Our unsupervised clustering analysis of these 154
genes revealed 3 (A, B, and C) clusters and 9 (A-1 through
A-4, B-1 through B-3 and C-1 to C-2) sub-clusters (Fig. 2).
Without UV treatment, the expression levels of genes in A,
B and C clusters in UACC903(+6) were higher than, equal
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Comparison
p -values
Fig. 1 Bar graph of the TUNEL-positive apoptotic cells and G2/M
phase cells before and after UV irradiation. TUNEL-positive cells:
UACC903 and UACC903(+6) cells before and at 12 h after the UV
irradiation were processed by the terminal deoxynucleotidyl trans-
ferase-mediated dUTP biotin nick-end labeling (TUNEL) assay using
the In Situ Cell Death Detection Kit (TMR, Roche). On average, 700
cells were analyzed for each of triplicate experiments to calculate
means and SD of the TUNEL-positive cells. G2/M-phase cells:
UACC903 and UACC903(+6) cells were sorted based on DNA
contents after staining, with propidium iodide (PI), UACC903 and
UACC903(+6) cells before and at 12 h after the UV irradiation.
10,000 cells were sorted using ELITE Flow Cytometry (Beckman
Coulter) and analyzed with Cell Quest software (Becton Dickinson).
Means and SD were calculated from triplicate experiments. The P-
values between comparisons are indicated. 903: UACC903, 9036:
UACC903(+6), 903UV: UACC903 treated with UV, 9036UV:
UACC903(+6) treated with UV
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123to and lower than those in UACC903, respectively. At 1.5-,
3-, 6- and 12-h after UV treatment, genes in all 9 sub-
clusters displayed signiﬁcant (P\0.05) up- or down-reg-
ulation at more than one time point, in either one cell line
or both. These sub-clusters revealed downregulated (A-1)
and upregulated (A-4 and B-2) genes in both cell lines,
upregulated genes in UACC903(+6) (B-3 and C-1) and
UACC903 (A-2 and B-1), and a mixture of both up- and
down-regulated genes (A-3 and C-2), in response to the UV
treatment (Fig. 2).
qRT-PCR validation of gene expression
To validate the microarray results, we conducted qRT-PCR
analysis on 11 genes including proapoptotic genes (BAK1,
FAS and CASP3), antiapoptotic genes (BCL2L1 and
MCL1), DNA damage repair genes (FANCD2 and UNG),
others (AMD1, DHX16 and PPP2CA) and the control
GAPDH, in UACC903 and UACC903(+6) cell lines
before (0-h) and at 3- and 12-h after the UV treatment. The
results indicated that out of 30 datapoints tested (10 genes
Fig. 2 Heat map of gene expression. UACC903(+6) and UACC903
cellsweretreatedwithorwithouttheUVirradiation.The‘‘0’’indicates
that the cells were harvested with the mock treatment, that is, without
UV irradiation. Other cells were harvested at 1.5-, 3-, 6- and 12-h time
points after the UV treatment. The samples were arranged on the top as
such to reveal a symmetrical comparison between UACC903(+6) and
UACC903andatimingcourseforeachcelllineaftertheUVtreatment.
Theexpressionratiosbetween UACC903(+6)andUACC903(+6/903
and903/+6)werecalculatedandplacedinthemiddleforthesymmetric
clustering analysis. The ‘0/0’ is calculated by dividing an individual
valuewiththemeanvalueatthe0timepoint,whichprovidesthecontrol
reference (black) for up- (red) and down- (green) regulation or no-
change in expression (black) of a gene. The UV-induced expression
changes were calculated by comparisons of a gene expression level at
each time point with themean value atthe 0time point,that is, 1.5/0, 3/
0, 6/0 and 12/0. The triplicate experiments (indicated as 1, 2, 3) were
performed for each time point. The clusters without UV treatment are
indicated by (a) 68 genes with expression levels signiﬁcantly
(P\0.05) higher in UACC903(+6) cell line than in UACC903, (b)
47geneswithoutsigniﬁcant(P[0.05)changesbetweenthesetwocell
line, and (c) 39 genes with expression levels signiﬁcantly (P\0.05)
lower in UACC903(+6) than in UACC903. The sub-clusters (A-1
through A-4, B-1 through B-3, C-1 and C-2) indicate the UV-induced
changes in expression. The gene symbols are indicated and please see
website http://www.gwumc.edu/biochem/faculty/su.html for gene IDs
and names
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123at 3 time-points, n = 30), 28 (93.3%) were in agreement
with the microarray results, including 21 (70%) with
agreement in both change (down, no change, or up) and
signiﬁcance (P\or[0.05) and 7 (23.3%) with agreement
in change but not in signiﬁcance (Fig. 3). The expression
of 2 genes (6.7%) was inconsistent and included BAK1 at
the 0-h time point and MCL1 at the 3-h time point (Fig. 3).
These results demonstrated overall agreement between the
microarray data and the qRT-PCR results. Thus, all 154
genes were subjected to further analysis.
Expression patterns of genes involved in proapoptosis
(16 genes), antiapoptosis (3 genes), DNA damage
repair (5 genes) and G2 checkpoint (1 gene) before
and after UV treatment
To ﬁnd genes controlling key phenotypic differences (i.e.,
apoptosis and G2/M phase transition [Fig. 1]) between
UACC903(+6) and UACC903 cells, our ontology analysis
of the 154 differentially expressed genes revealed 16
proapoptotic genes, 3 antiapoptotic genes, 1 G2 checkpoint
gene, and 5 DNA damage repair genes (Fig. 4a). Without
UV treatment, 10 proapoptotic genes (FDX1, BCAP31,
BNIP1, VDAC1, FDXR, BAK1 [encoded by 6p21.3],
TNFSF10, FAS, CASP6 and CASP3) were all upregulated
in UACC903(+6) and downregulated in UACC903, while
the expression of 5 proapoptotic genes (BAD, BID, BBC3,
CYCS and APAF1) displayed no signiﬁcant change. In
response to the UV treatment, signiﬁcantly (P\0.05)
upregulated FDX1, BAD and BID, downregulated FDXR,
BAK1, TNFSF10, FAS, CASP6, CASP3 and APAF1, and
insigniﬁcantly changed BCAP31, BNIP1, VDAC1, BBC3
and CYCS were identiﬁed in UACC903(+6) cells. In
comparison, identiﬁcation in UACC903 cells of signiﬁ-
cantly upregulated 12 genes (FDX1, BCAP31, BNIP1,
VDAC1, FDXR, BAK1, TNFSF10, FAS, CASP6, CASP3,
BBC3 and CYCS), downregulated APAF1, and did not
change BAD and BID (Fig. 4a) were noted. Without UV
treatment, 3 antiapoptotic genes (CLN3, MCL1 and
BCL2L1) were upregulated in UACC903(+6) and down-
regulated in UACC903. The UV treatment induced
downregulation of MCL1 and BCL2L1 in UACC903(+6)
and upregulation of all 3 genes in UACC903. CLN3
expression in UACC903(+6) did not respond to UV irra-
diation (Fig. 4a).
Five genes with DNA damage repair function, including
FANCD2, APEX1, APEX2, UNG and TP53, displayed no
signiﬁcant changes in expression between UACC903(+6)
and UACC903 without UV treatment. In contrast,
FANCD2, APEX1 and APEX2 were all upregulated in
UACC903 in response to UV treatment (Fig. 4a).
FANCD2 is also required to maintain the DNA damage-
induced G2 checkpoint. UNG expression was downregu-
lated in UACC903(+6) cells at the 3-h time point but
Fig. 3 Consistent RNA levels
measured by microarray and
qRT-PCR. (a) Relative RNA
ratios of 10 genes, each at 3
time points, between UACC903
and UACC903(+6) cell lines
measured by microarrays. (b)
Relative RNA levels of the
same 10 genes, each at the same
3 time points, measured by
qRT-PCR. The ‘+’ sign
indicates P\0.05, and the ‘*’
indicates P\0.01 for a pair
within measurement. Out of
these 30 gene-and-time-point
comparisons, 28 (93.3%) are
consistent between these two
types of measurements,
including 21 (70%) with
agreement in both change
(down, no, or up) and P-value,
and 7 (23.3%) consistent with
the changes but not with P-
value (underlined). Two (6.7%)
was inconsistent and included
BAK1 at 0-h time point and
MCL1 at 3-h time point
(arrowhead)
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123upregulated in UACC903 cells at the 6-h time point.
Although TP53 is known to be involved in both apoptosis
and DNA damage repair, its expression was downregulated
in both cell lines in response to UV treatment (Fig. 4a).
Survival-apoptosis signaling pathways
with differentially expressed genes (n = 19)
in UACC903(+6) and UACC903 cells before
and after UV treatment
We mapped the aforementioned 16 proapoptosis genes and
3 antiapoptosis genes to known molecular signaling path-
ways that regulate survival and apoptosis of cells. The
results revealed mitochondria-centered signaling pathways
with a total of 35 gene products (Fig. 4b). Without UV
irradiation, the expression of 10 proapoptotic genes
(TNFSF10, FAS, BNIP1, BAK1 [encoded by 6p21.3],
BCAP31, FDX1, FDXR, VDAC1, CASP6 and CASP3)
and 3 antiapoptotic genes (BCL2L1, CLN3 and MCL1)
were signiﬁcantly (P\0.05) higher in the UACC903(+6)
cell line (red) than in UACC903 (green). Six genes (BBC3,
BID, TP53, BAD, CYCS and APAF1) had no signiﬁcant
change in expression (black). Expression changes of 11
genes (FADD, CASP8, CASP10, CASP2, BAX, HtrA2,
DIABLO, AIFM1, AIFM2, ENDOG, CASP7) were not
detected. The expression status of the remaining 5 genes
(FASLG, TNFSF10A, DAXX, IAP and CASP9) was
unknown (italic) due to the absence from the microarray.
Fig. 4 Heat map and survival-apoptosis pathways. (a) Heat map of
15 proapoptotic, 3 antiapoptotic, and 5 DNA-damage-repair genes in
UACC903(+6) and UACC903 cell lines before (0) and at 1.5-, 3-, 6-,
and 12-h after the UV treatment. The color map illustrates a color
change corresponding to a ratio change. Each ratio was calculated by
dividing an expression level of a given gene at the time point to the
mathematic mean value of the gene expression levels in both
UACC903(+6) and UACC903 cells without UV treatment. The
arrowheads and hyphens indicate overall expression changes of a
gene in response to the UV treatment. (b) The survival-apoptosis
pathways with differentially expressed genes between UACC903(+6)
and UACC903 cell lines without UV treatment. Red, green and black
correspond to those at the 0-h time point in UACC903(+6) and
UACC903 cell line listed in the panel (A). The left and right half in
each gene plate represents relative expression levels between
UACC903(+6) and UACC903, respectively. Solid line with solid
arrowhead: direct activation of expression or activity; dashed line:
indirect; open arrowhead: translocation; line with a short line at one
end: inhibition; line with circle: leading to; square: cytokine; double
circles or rhombus: group or complex; rhombus: enzymes; circle:
named protein; membrane: cell membrane
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123The known interactions of these genes are indicated in the
pathways. The differential gene expression pattern in these
survival-apoptosis signaling pathways appears to predict
the UACC903(+6) cell line’s sensitivity, compared to the
UACC903’s resistance to apoptosis (Fig. 4b).
Validation of expression changes of proapoptotic
(BAK1 and FAS) and antiapoptotic (BCL2L1
and MCL1) proteins
To correlate mRNA levels to protein expression, Western
blot analysis of proapoptotic proteins (BAK1 and FAS),
antiapoptotic proteins (BCL2L1 and MCL1), and control
(GAPDH) was performed for these two cell lines before
and after UV treatment. The relative protein levels from
two independent Western blots were scanned and normal-
ized to GAPDH. The results indicated that without UV
treatment the protein levels of BAK1, BCL2L1 and FAS
were at least threefold higher and the MCL1 protein was
1.6-fold greater in UACC903(+6) cells than in UACC903
(Fig. 5). After the UV treatment these proteins maintained
high expression levels in UACC903(+6), with some
decrease of BAK1, BCL2L1 and FAS proteins at 6- and
12-h time points. In comparison, all 4 proteins in
UACC903 remained the same or were modestly reduced at
1.5-, 3- and 6-h time points, while increasing slightly at the
12-h time point (Fig. 5).
Functional validation of the differential
survival-apoptosis signaling pathways
To validate the survival-apoptosis signaling pathways, we
performed MTS cell proliferation assays comparing via-
bility after parallel treatment of UACC903(+6) and
UACC903 cells with FASLG. The results indicated that cell
survival was a function of dose and time following FASLG
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Fig. 5 Western blots and
quantiﬁcation. (a) Western blot
of cell lysate from
UACC903(+6) and UACC903
cell lines before (0) and at 1.5-,
3-, 6-, and 12-h after the UV
treatment, using the antibodies
against BAK1, BCL2L1, FAS,
MCL1 and GAPDH proteins.
GAPDH was used as a control
for loading error. (b) Bar graph
for the quantitative comparison
among protein expression
levels. The signal intensities of
a protein band and its
surrounding background were
scanned from images derived
from two independent Western
experiments for each protein
and quantiﬁed by using
Scanalytics IPLAB 3.6
(Rockville, MD). The resultant
background-subtracted values of
protein expression were
normalized to those of GAPDH
and then plotted as the relative
protein levels for each protein at
each time point in each cell line
with or without UV treatment
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123treatment, and that the survival of UACC903(+6) cells was
signiﬁcantly less than that of UACC903 (Fig. 6a and b).
Speciﬁcally, at the dose of 50, 100, 200, or 400 ng/ml
FASLG, UACC903(+6) cells had 66 ± 7.1%, 57 ± 7.0%,
52 ± 5.0% and 33 ± 4.7% survival, but UACC903 had
94 ± 3.8%, 86 ± 3.9%, 78 ± 2.7% and 76 ± 5.5% sur-
vival, respectively. The difference at each corresponding
dose was highly signiﬁcant (P\0.002). At 1.5-, 3-, 6-, 12-
and 24-h after treatment with 100 ng/ml FASLG, the
UACC903(+6) cell survival was reduced to 91 ± 1.9%,
82 ± 4.9%, 64 ± 5.8%, 35 ± 14.4%, and 58 ± 6.5%,
respectively; while the corresponding UACC903 cell
survival was 98 ± 10.6%, 93 ± 4.4%, 90 ± 15.2%,
70 ± 5.4% and 83 ± 2.4%. The survival difference
between these two cell lines was insigniﬁcant (P = 0.332)
at the 1.5-h time point, signiﬁcant at 3- and 6-h time points
(P = 0.050), and highly signiﬁcant at 12-h (P = 0.016) and
24-h (P = 0.003) time points (Fig. 6a and b).
To further validate the survival-apoptosis signaling
pathway, we determined the effects of siRNA knockdown
of the proapoptotic protein BAK1 on survival of
UACC903(+6) cells in the presence or absence of FASLG.
The results indicate that transfection with BAK1 siRNA
(BAK1-siR) signiﬁcantly (P = 0.0102) increased cell sur-
vival by 114 ± 6.4% greater than mock transfection
(100 ± 8.3%). Western blot analysis indicated that BAK1
protein was knocked down to 37.7% of mock transfection.
Moreover, in the absence of BAK1 siRNA, FASLG-
induced cell death was 77 ± 6.0% (P = 0.0003); whereas
in the presence, the FASLG-induced cell death was
94 ± 7.0% which is insigniﬁcantly different from mock
transfection (P = 0.2323), but highly signiﬁcantly differ-
ent from the treatment with either BAK1 siRNA
(114 ± 6.4%, P = 0.0006) or FASLG (77 ± 6.0%,
P = 0.0010) alone (Fig. 6c and d).
Discussion
This study identiﬁed survival-apoptosis molecular signal-
ing pathways with differentially expressed genes
underlying resistance and sensitivity to apoptosis of human
malignant melanoma cell line UACC903 and the chromo-
some 6-mediated suppressed cell line UACC903(+6).
UACC903 cells displayed resistance to apoptosis and G2/
M arrest at signiﬁcantly higher levels than UACC903(+6)
regardless of UV treatment. In contrast, UACC903(+6)
cells had a low level of constitutive apoptosis, which
increased by[5-fold in response to UV irradiation (Fig. 1).
By applying human mitochondria-focused cDNA micro-
arrays, we identiﬁed the difference in the survival-
apoptosis signaling pathways between these two cell lines
(Fig. 4). The expression changes of a number of repre-
sentative genes were validated by qRT-PCR and Western
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123blots. The FASLG-induced dose- and time-responsive cell
deaths were exploited to functionally validate the differ-
ential survival-apoptosis signaling pathways. Moreover,
siRNA knockdown of the upregulated proapoptotic protein
BAK1, encoded at chromosome 6p21.3, in UACC903(+6)
cells not only enhanced cell survival, but also attenuated
FASLG-induced cell death further validating this pathway.
Thus, the identiﬁed differential survival-apoptosis signal-
ing pathways provide a molecular mechanism underlying
resistance and sensitivity to apoptosis of these two mela-
noma cell lines (UACC903 and UACC903[+6]).
The survival-apoptosis molecular signaling pathway
contains gene products involved in multiple proapoptotic
and antiapoptotic signaling pathways, including extrinsic
and intrinsic, caspase-dependent and -independent, mito-
chondria-centered, and other organelle-related paths.
Homeostasis between proapoptosis and antiapoptosis may
be a key factor regulating life and death of cells [26–28].
For example, in the extrinsic, caspase-dependent apoptosis
pathway, the proapoptotic proteins TNFSF10 and FAS are
known to induce apoptosis as immune response, through
activation of CASP8 and CASP10, which in turn activate
CASP3 and CASP6, leading to apoptosis. The UACC903
cell line’s signiﬁcantly lower expression of 10 proapoptotic
genes (in contrast to only 3 antiapoptotic genes) than the
UACC903(+6) cell line may explain why the former had
fewer constitutive and UV- or FASLG-induced cell deaths
than the latter. Apparently, multiple proteins in the sur-
vival-apoptosis signaling pathways participate in the
resistance of UACC903 and the sensitivity of
UACC903(+6) to apoptosis. The approach employed and
pathways identiﬁed by this study may facilitate therapeutic
research aimed at discovery of drugs and drug targets.
The FAS and FASLG system comprises a major path-
way for the induction of apoptosis in cells and tissues that
play central roles in the physiological regulation of tissue
remodeling, the pathogenesis of various malignancies, and
diseases of the immune response. FAS, also known as
TNFRSF6/APT1/CD95, is a cell surface receptor and a
member of the tumor necrosis factor (TNF)-receptor
superfamily. Its ligand FASLG, also known as TNFSF6/
APT1LG1/CD95L, can trigger apoptosis by cross-linking
with FAS [29, 30]. Since FAS-FASLG signaling is nec-
essary and sufﬁcient to control keratinocyte apoptosis of
the epidermis exposed to UV-light, it thus plays a crucial
role in regulation of UV-induced DNA damage-triggered
apoptosis [31].
Our study reveals that the FAS-FASLG signaling path-
way, which interacts with the DNA damage-triggered
apoptosis pathway, consists of multiple genes with altered
expression between human malignant melanoma cell line
UACC903 and the suppressed cell line UACC903(+6).
Signiﬁcantly more UACC903 cells arrest in the G2/M
phase, constitutive and UV-induced, than UACC903(+6)
cells. The UV treatment causes damage to DNA; and cells
with excessive DNA damage undergo apoptosis, prevent-
ing abnormal growth [32, 33]. The G2/M-arrest,
particularly the arrested UACC903 cells induced by the
UV irradiation, may undergo DNA damage repair. This
hypothesis is supported by the fact that genes involved in
the cell cycle G2 checkpoint (FANCD2) [34] and DNA
damage repair (FANCD2, APEX1, APEX2 and UNG)
were all upregulated in the UV-treated UACC903 cells. In
contrast, none of these genes responded to UV treatment in
UACC903(+6) cells (Fig. 4a). It is known that FANCD2
protein involves in the homology-directed DNA repair [35,
36], APEX1 and APEX2 repair apurinic/apyrimidinic sites
[37, 38], and UNG initiates the base-excision repair (BER)
[39]. These genes provide molecular clues for further
study of G2/M arrest and DNA damage repair that may
play a key role in development of human malignant
melanomas.
In the present study, we found striking UV-induced
changes in expression patterns between the UACC903(+6)
and UACC903 cell lines. The unsupervised clustering
analysis of 154 genes revealed 3 clusters and 9 sub-clusters
of genes. The fact that at least 4 sub-clusters (A-2, B-1, B-3
and C-1) consisting of 104 genes displayed signiﬁcantly
different expression patterns between these two cell lines in
response to the UV treatment (Fig. 2) strongly suggests the
different regulatory mechanisms controlling expression of
these genes. Differences in expression of so many genes
suggest the presence of different control mechanisms
underlying expression of these genes, either directly or
through cascade effect. Probably, all of these differentially
expressed genes contribute to the phenotypic differences
between the malignant melanoma cell line UACC903 and
the chromosome 6-mediated suppressed cell line
UACC903(+6).
Changes in protein expression lag behind RNA changes.
The comparisons between RNA expression and protein
expression of four genes including BAK1, BCL2L1, FAS
and MCL1 indicate that the RNA changes occurred earlier
than the protein in response to UV treatment (Figs. 4a and
5). In addition, the changes in expression patterns of
BAK1, BCL2L1, FAS and MCL1 RNA and protein were
very similar. These results suggest that these 4 genes may
be regulated at both transcriptional and translational levels
in response to UV treatment.
To date, a number of genes encoded by human chro-
mosome 6 have been shown to be involved in chromosome
6-mediated suppression of CMM phenotypes. Church et al.
identiﬁed the mitochondrial antioxidant enzyme manga-
nese superoxide dismutase 2 (SOD2) (6q25.3) as a tumor
suppressor gene that inhibits colony formation in soft agar
and tumors in nude mice [40]. Our previous study revealed
1002 Apoptosis (2008) 13:993–1004
123up- and down-regulation of gap junction protein alpha 1
(GJA1) (6q21-q23.2), also known as connexin 43 (Cx43),
in UACC903(+6) and UACC903, respectively, and dem-
onstrated the suppression of colony formation of
UACC903 cells in soft agar by transfection and overex-
pression of GJA1 [17]. Other investigators reported that
GJA1 inhibits proliferation of glioblastoma cell lines [41],
lung carcinoma cell line PG [42], prostate cancer cell line
LNCap [43] and breast cancer cell line MDA-MB-231 [44]
in vitro and in nude mice. Goldberg et al discovered the
transcriptional coactivator CRSP3/MED23 (6q22.33-
q24.1) as a metastasis suppressor by upregulation of a
metastasis suppressor gene KISS1 [45]. In the current study
we demonstrated that upregulation of BAK1 (6p21.3) RNA
and protein was associated with the UACC903(+6) cell
line’s sensitivity to apoptosis, and that siRNA downregu-
lation of BAK1 protein led to an increase in the cell
survival. Taken together, all these studies demonstrated
that chromosome 6-mediated tumor suppression involves
an abnormal expression of genes to regulate survival (i.e.,
SOD2), apoptosis (i.e., BAK1), proliferation (i.e., GJA1),
and transcription (i.e., CRSP3). These complex molecular
changes may be different in different genetic backgrounds
or cancer cells. Accordingly, this type of heterogeneity
requires the genomic and proteomic studies of an individ-
ual clone of cancer cells derived from different (or even the
same) patients for complete mapping and understanding of
the molecular basis underlying the cell behavior, and for
the development of diagnostic and/or therapeutic methods.
Acknowledgments The authors thank Dan Sackett for his critical
review of the manuscript. This work was supported by NIH-NIDDK-
06-925, the Catherine B McCormick Genomics Center, and a gift
from the St. Laurent Institute. P.H. was supported by Division of
Hematology, Center for Biological Evaluation and Research, Food
and Drug Administration. O.M.R. was supported by Program in
Reproductive and Adult Endocrinology, Laboratory of Clinical
Genomics, Eunice Kennedy Shriver National Institute of Child Health
and Human Development, National Institutes of Health. Authors state
that there are no any competing ﬁnancial, professional, or personal
conﬂicts of interest related to this publication.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. American Cancer Society (2007) Cancer facts and ﬁgures 2007.
American Cancer Society, Atlanta, pp 1–54
2. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma
biology and new targeted therapy. Nature 445:851–857. doi:
10.1038/nature05661
3. Meier F, Satyamoorthy K, Nesbit M et al (1998) Molecular
events in melanoma development and progression. Front Biosci
3:D1005–D1010
4. Kim R, Emi M, Tanabe K (2006) The role of apoptosis in cancer
cell survival and therapeutic outcome. Cancer Biol Ther 5:1429–
1442
5. Su YA, Trent JM (1995) Genetics of cutaneous malignant mel-
anoma. Cancer Control 2:392–397
6. Thompson FH, Emerson J, Olson S et al (1995) Cytogenetics of
158 patients with regional or disseminated melanoma. Subset
analysis of near-diploid and simple karyotypes. Cancer Genet
Cytogenet 83:93–104. doi:10.1016/0165-4608(95)00057-V
7. Sargent LM, Nelson MA, Lowry DT et al (2001) Detection of
three novel translocations and speciﬁc common chromosomal
break sites in malignant melanoma by spectral karyotyping.
Genes Chromosomes Cancer 32:18–25. doi:10.1002/gcc.1162
8. Pathak S, Drwinga HL, Hsu TC (1983) Involvement of chro-
mosome 6 in rearrangements in human malignant melanoma cell
lines. Cytogenet Cell Genet 36:573–579
9. Trent JM, Thompson FH, Meyskens FL Jr (1989) Identiﬁcation
of a recurring translocation site involving chromosome 6 in
human malignant melanoma. Cancer Res 49:420–423
10. Millikin D, Meese E, Vogelstein B et al (1991) Loss of hetero-
zygosity for loci on the long arm of chromosome 6 in human
malignant melanoma. Cancer Res 51:5449–5453
11. Walker GJ, Palmer JM, Walters MK et al (1994) Simple tandem
repeat allelic deletions conﬁrm the preferential loss of distal
chromosome 6q in melanoma. Int J Cancer 58:203–206. doi:
10.1002/ijc.2910580210
12. Trent JM, Stanbridge EJ, McBride HL et al (1990) Tumorige-
nicity in human melanoma cell lines controlled by introduction of
human chromosome 6. Science 247:568–571. doi:10.1126/
science.2300817
13. Welch DR, Chen P, Miele ME et al (1994) Microcell-mediated
transfer of chromosome 6 into metastatic human C8161 mela-
noma cells suppresses metastasis but does not inhibit
tumorigenicity. Oncogene 9:255–262
14. Miele ME, Robertson G, Lee JH et al (1996) Metastasis sup-
pressed, but tumorigenicity and local invasiveness unaffected, in
the human melanoma cell line MelJuSo after introduction of
human chromosomes 1 or 6. Mol Carcinog 15:284–299. doi :
10.1002/(SICI)1098-2744(199604)15:4\284::AID-MC6[3.0.CO;
2-G
15. Zhang Q, Chen Y, Wang BD et al (2007) Differences in apoptosis
and cell cycle distribution between human melanoma cell lines
UACC903 and UACC903(+6), before and after UV irradiation.
Int J Biol Sci 3:342–348
16. Su YA, Ray ME, Lin T et al (1996) Reversion of monochro-
mosome-mediated suppression of tumorigenicity in malignant
melanoma by retroviral transduction. Cancer Res 56:3186–3191
17. Su YA, Bittner ML, Chen Y et al (2000) Identiﬁcation of tumor-
suppressor genes using human melanoma cell lines UACC903,
UACC903(+6), and SRS3 by comparison of expression proﬁles.
Mol Carcinog 28:119–127. doi :10.1002/1098-2744(200006)28:
2\119::AID-MC8[3.0.CO;2-N
18. Bai X, Wu J, Zhang Q et al (2007) Third-generation human
mitochondria-focused cDNA microarray and its bioinformatic
tools for analysis of gene expression. Biotechniques 42:365–375
19. Darzynkiewicz Z, Li X, Gong J (1994) Assays of cell viability:
discrimination of cells dying by apoptosis. Methods Cell Biol
41:15–38
20. Vermes I, Haanen C, Steffens-Nakken H et al (1995) A novel
assay for apoptosis. Flow cytometric detection of phosphatidyl-
serine expression on early apoptotic cells using ﬂuorescein
labelled Annexin V. J Immunol Methods 184:39–51. doi:10.1016/
0022-1759(95)00072-I
Apoptosis (2008) 13:993–1004 1003
12321. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identiﬁcation of
programmed cell death in situ via speciﬁc labeling of nuclear
DNA fragmentation. J Cell Biol 119:493–501. doi:10.1083/jcb.
119.3.493
22. Ben-Sasson SA, Sherman Y, Gavrieli Y (1995) Identiﬁcation of
dying cells—in situ staining. Methods Cell Biol 46:29–39. doi:
10.1016/S0091-679X(08)61922-6
23. Manoli I, Le H, Alesci S et al (2005) Monoamine oxidase-A is a
major target gene for glucocorticoids in human skeletal muscle
cells. FASEB J 19:1359–1361
24. Eisen MB, Spellman PT, Brown PO et al (1998) Cluster analysis
and display of genome-wide expression patterns. Proc Natl Acad
Sci USA 95:14863–14868. doi:10.1073/pnas.95.25.14863
25. Holland PM, Abramson RD, Watson R et al (1991) Detection of
speciﬁc polymerase chain reaction product by utilizing the 50-30
exonuclease activity of Thermus aquaticus DNA polymerase.
Proc Natl Acad Sci USA 88:7276–7280. doi:10.1073/pnas.88.
16.7276
26. Belizario JE, Alves J, Occhiucci JM et al (2007) A mechanistic
view of mitochondrial death decision pores. Braz J Med Biol Res
40:1011–1024. doi:10.1590/S0100-879X2006005000109
27. Eberle J, Fecker LF, Hossini AM et al (2008) Apoptosis pathways
and oncolytic adenoviral vectors: promising targets and tools to
overcome therapy resistance of malignant melanoma. Exp Der-
matol 17:1–11. doi:10.1159/000109583
28. Kulms D, Schwarz T (2002) Mechanisms of UV-induced signal
transduction. J Dermatol 29:189–196. doi:10.1159/000065313
29. Sharma K, Wang RX, Zhang LY et al (2000) Death the Fas way:
regulation and pathophysiology of CD95 and its ligand. Phar-
macol Ther 88:333–347. doi:10.1016/S0163-7258(00)00096-6
30. Kavurma MM, Khachigian LM (2003) Signaling and transcrip-
tional control of Fas ligand gene expression. Cell Death Differ
10:36–44. doi:10.1038/sj.cdd.4401179
31. Guzman E, Langowski JL, Owen-Schaub L (2003) Mad dogs,
Englishmen and apoptosis: the role of cell death in UV-induced
skincancer.Apoptosis8:315–325.doi:10.1023/A:1024112231953
32. Wei Q, Lee JE, Gershenwald JE et al (2003) Repair of UV light-
induced DNA damage and risk of cutaneous malignant mela-
noma. J Natl Cancer Inst 95:308–315
33. Banerjee G, Gupta N, Kapoor A et al (2005) UV induced
bystander signaling leading to apoptosis. Cancer Lett 223:275–
284. doi:10.1016/j.canlet.2004.09.035
34. Freie BW, Ciccone SL, Li X et al (2004) A role for the Fanconi
anemia C protein in maintaining the DNA damage-induced G2
checkpoint. J Biol Chem 279:50986–50993. doi:10.1074/jbc.
M407160200
35. Garcia-Higuera I, Taniguchi T, Ganesan S et al (2001) Interaction
of the Fanconi anemia proteins and BRCA1 in a common path-
way. Mol Cell 7:249–262. doi:10.1016/S1097-2765(01)00173-3
36. Hussain S, Wilson JB, Medhurst AL et al (2004) Direct interaction
of FANCD2 with BRCA2 in DNA damage response pathways.
Hum Mol Genet 13:1241–1248. doi:10.1093/hmg/ddh135
37. Chou KM, Cheng YC (2002) An exonucleolytic activity of
human apurinic/apyrimidinic endonuclease on 30 mispaired DNA.
Nature 415:655–659. doi:10.1038/415655a
38. Burkovics P, Szukacsov V, Unk I et al (2006) Human Ape2
protein has a 30-50 exonuclease activity that acts preferentially on
mismatched base pairs. Nucleic Acids Res 34:2508–2515. doi:
10.1093/nar/gkl259
39. Kavli B, Sundheim O, Akbari M et al (2002) hUNG2 is the major
repair enzyme for removal of uracil from U:A matches, U:G
mismatches, and U in single-stranded DNA, with hSMUG1 as a
broad speciﬁcity backup. J Biol Chem 277:39926–39936. doi:
10.1074/jbc.M207107200
40. Church SL, Grant JW, Ridnour LA et al (1993) Increased man-
ganese superoxide dismutase expression suppresses the malignant
phenotype of human melanoma cells. Proc Natl Acad Sci USA
90:3113–3117. doi:10.1073/pnas.90.7.3113
41. Huang RP, Fan Y, Hossain MZ et al (1998) Reversion of the
neoplastic phenotype of human glioblastoma cells by connexin 43
(cx43). Cancer Res 58:5089–5096
42. Zhang ZQ, Zhang W, Wang NQ et al (1998) Suppression of
tumorigenicity of human lung carcinoma cells after transfection
with connexin43. Carcinogenesis 19:1889–1894. doi:10.1093/
carcin/19.11.1889
43. Mehta PP, Perez-Stable C, Nadji M et al (1999) Suppression of
human prostate cancer cell growth by forced expression of
connexin genes. Dev Genet 24:91–110. doi :10.1002/(SICI)1520-
6408(1999)24:1/2\91::AID-DVG10[3.0.CO;2-#
44. Qin H, Shao Q, Curtis H et al (2002) Retroviral delivery of
connexin genes to human breast tumor cells inhibits in vivo
tumor growth by a mechanism that is independent of signiﬁcant
gap junctional intercellular communication. J Biol Chem
277:29132–29138. doi:10.1074/jbc.M200797200
45. Goldberg SF, Miele ME, Hatta N et al (2003) Melanoma
metastasis suppression by chromosome 6: evidence for a pathway
regulated by CRSP3 and TXNIP. Cancer Res 63:432–440
1004 Apoptosis (2008) 13:993–1004
123